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12 new susceptibility loci for prostate cancer
identified by genome-wide association study in
Japanese population
Ryo Takata et al.#
Genome-wide association studies (GWAS) have identified ~170 genetic loci associated with
prostate cancer (PCa) risk, but most of them were identified in European populations. We
here performed a GWAS and replication study using a large Japanese cohort (9,906 cases
and 83,943 male controls) to identify novel susceptibility loci associated with PCa risk. We
found 12 novel loci for PCa including rs1125927 (TMEM17, P= 3.95 × 10−16), rs73862213
(GATA2, P= 5.87 × 10−23), rs77911174 (ZMIZ1, P= 5.28 × 10−20), and rs138708 (SUN2, P=
1.13 × 10−15), seven of which had crucially low minor allele frequency in European population.
Furthermore, we stratified the polygenic risk for Japanese PCa patients by using 82 SNPs,
which were significantly associated with Japanese PCa risk in our study, and found that early
onset cases and cases with family history of PCa were enriched in the genetically high-risk
population. Our study provides important insight into genetic mechanisms of PCa and
facilitates PCa risk stratification in Japanese population.
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The incidence of prostate cancer (PCa) among Asian maleshas been dramatically rising even though it is still lowercompared to that in western countries1. In 2015, PCa
became the most common cancer type among Japanese males2.
The best-known risk factor for PCa is family history3. A patient
with a family history of PCa in first-degree relative has twice the
risk of developing PCa during his lifetime compared to a patient
without a family history, indicating a strong influence of inherited
genetics on PCa susceptibility3. Early onset PCa is also recognized
as a marker of genetic susceptibility for hereditary PCa, and PCa
cases with rare variants of BRCA2 and HOXB13 constitute 2.0
and 3.1% of early onset cases4,5. To identify genetic poly-
morphisms associated with PCa, a number of genome-wide
association studies (GWASs) have been conducted, which iden-
tified ~170 risk loci associated with PCa6–10. However, most of
these studies were carried out for population of European
ancestry or cohorts of mixed ethnicity. The considerable diversity
of genetic background between different populations as shown by
1000 Genomes Project, together with the large difference in the
incidence of PCa among ethnic groups, suggests a role of genetic
risk factors in PCa disparities11,12. Even though a recent study
suggests that the number of genetic loci associated with PCa has
almost saturated after studying more than a hundred thousand
patients10, it is possible that even more PCa associated risk loci
will be identified by studying populations of non-European
ancestry.
We have initially identified five PCa associated risk loci by
GWAS in the Japanese population13, with a further meta-analysis
in the Japanese population revealing three additional loci for PCa
susceptibility14. We have also developed a highly reproducible
polygenic risk estimation model for PCa detection, confirming
polygenic risk of PCa in the Japanese population15. However, it is
possible that increasing sample size will further improve power
and may lead to the identification of yet-identified risk loci in this
population. Moreover, it remains to be known which of the ~140
risk loci associated with PCa in the European ancestry population
are also reproducible in the Asian population.
In this study, we have performed an even larger GWAS using
an independent Japanese cohort to identify novel susceptibility
loci associated with PCa and also validate the association of the
previously reported risk loci with PCa risk in the Japanese
population. Furthermore, we stratified the polygenic risk for
Japanese PCa patients by using 82 significant single nucleotide
polymorphisms (SNPs) and examined clinical feature of those at
genetically high risk.
Results
GWAS in the Japanese population. The overall design of the
GWAS is depicted in Fig. 1. 5088 cases of PCa from Biobank
Japan (BBJ) were included16,17. The controls consisted of 10,682
Japanese male subjects from four large cohort studies (the Japan
Multi-Institutional Collaborative Cohort (J-MICC) study, the
Japan Public Health Center-based Prospective (JPHC) study,
Iwate Medical Megabank Organization (IMM), and Tohoku
Medical Megabank Organization (ToMMo)) who had never been
diagnosed with PCa18–20. Detailed clinical characteristics of the
subjects are shown in Supplementary Table 1. After quality
control, the association study was performed for 523,051 SNPs.
All case and control samples belonged to the same cluster in the
principal component analysis (Supplementary Fig. 1). A
quantile–quantile (Q-Q) plot revealed modest inflation of the test
statistics (λGC= 1.189); however, the value adjusted by the sample
size, λGC　1000, was 1.027 (Supplementary Fig. 2). We further
conducted imputation analysis using the data of 275 Asians in the
1000 Genomes Project Phase 1 as a reference (JPT: 89, CHB: 97,
CHS: 89). As a result, 2997 SNPs represented P < 1 × 10−5 in
GWAS (Fig. 1). Many of these SNPs existed in independent
genetic regions including multiple loci at 8q24 (Fig. 2).
Replication study and novel PCa-susceptibility loci. Next, we
conducted an independent replication study using 4818 cases
from BBJ and JIKEI cohorts, and 73,261 male controls from the
BBJ cohort. Of the 2997 SNPs, we removed SNPs that showed low
imputation quality (R square < 0.3) and SNPs that have pre-
viously been reported to be associated with PCa. Then we selected
representative SNPs for each genetic region that showed the
strongest association with PCa in the same linkage disequilibrium
(LD) block. We also selected 20 SNPs which showed exception-
ally strong association with PCa compared to the other SNPs in
the same LD block. In total, we selected 101 SNPs for the repli-
cation study (Supplementary Table 2). In the replication study,
genotyping was conducted using multi-index sequencing and the
multiplex invader method (see Methods). Among the candidate
SNPs, five SNPs could not be genotyped by either method and
were excluded. When we combined both stages using the inverse
method, 12 SNPs which have not been reported previously were
identified to be significantly associated with PCa at P < 5 × 10−8
(Table 1).
Locus explore plot of each locus is shown in Fig. 3 and
Supplementary Fig. 321. All novel SNPs identified in this study
except rs138708 existed in non-exonic regions. Of the 12 new loci,
five loci (rs7542260 at chr.1, rs75777376 at chr.8, rs16901814 at
chr.8, rs4554825 at chr.10, and rs8023793 at chr.15) contained no
protein-coding genes in their LD blocks or in their vicinities
(within 100 kb). On the other hand, rs11125927 at chr.2 was
located at the intron of the TMEM17 gene. rs73862213 at chr.3
was located near GATA2. rs77911174 at chr.10 region included
ZMIZ1 gene. rs11055034 at chr.12 was in the intron of APOLD1
and the region also contained the 3’ end of CDKN1B. rs6117562
at chr.20 was in the region containing SLC52A3. rs138708 at
chr.22, formed a very large LD block with many genes, however,
rs138708 is a non-synonymous SNP in the exon of SUN2 gene.
The region spanning rs4826594 at chr.X included three genes,
FGD1, GNL3L, and TSR2.
Expression analysis of the new loci. It is possible that these SNPs
reside in enhancer or suppressor regions of nearby genes and
influence prostate carcinogenesis by altering the expression of
these genes. In order to check the association between the gen-
otype of newly identified SNPs and expression of the genes in
their 1 Mb proximity, we conducted eQTL analysis using the
GTEX database22. As a result, four SNPs showed weak association
with expression of nearby genes (P < 0.05, Supplementary
Table 3). Among them, rs16901814 showed association with
expression of the FAM84B gene which is 311 kb away from the
index SNP (P= 0.0204) (Supplementary Fig. 3b). Even though
the function of FAM84B is not well known, its expression is
elevated in various cancer, and its overexpression and copy
number gain in PCa is reported to be associated with poor
prognosis23. rs4554825 was associated with expression of ZMIZ1-
AS (P= 0.0361). As previously mentioned, ZMIZ1 is a gene that
was present in the LD block containing rs77911174 (Fig. 3c). It is
possible that both rs4554825 and rs77911174 are independently
associated with PCa by altering expression or function of ZMIZ1.
rs6117562 was associated with expression of FAM110A (P=
0.0104). FAM110A is a cell-cycle regulated gene whose function is
not well known. Families of FAM110 proteins localize to cen-
trosomes and are associated with microtubule aberrations24, and
FAM110A may affect prostate carcinogenesis through dysregu-
lation of cell-cycle progression. rs6117562 was also associated
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with CSNK2A1 expression (P= 0.0276), which is known as
responsible gene for Okur-Chung neurodevelopmental
syndrome25.
Association with the reported loci. Recent PCa GWAS have
analyzed more than one-hundred thousand patients and identi-
fied many genetic regions associated with PCa6–10. However,
these previous studies as well as meta-analysis have failed to
identify the 12 susceptibility loci identified in this study (Sup-
plementary Fig. 4). Among the novel loci identified, minor allele
frequency (MAF) in Caucasians were significantly lower com-
pared to that in the Japanese in seven loci, rs7542260, rs73862213,
rs75777376, rs4554825, rs77911174, rs138708, and rs4826594
(Supplementary Table 4). The difference in MAF likely accounts
for the lack of identification of these loci in previous studies. On
the other hand, the MAF in the European population did not
significantly differ from that in the Japanese for the other SNPs.
In these cases, LD structure pattern spanning the marker SNPs
might be different by population.
Since several of the SNPs newly identified in this study existed
in regions close to previously reported PCa susceptibility loci, we
checked the independency of association by conditional analysis
with GWAS data (Supplementary Table 5). rs721048, a known
PCa susceptibility loci, is located near a newly identified SNP,
rs11125927. However, rs11125927 was independently associated
with PCa (P= 1.02 × 10−9) in the conditional analysis. We also
checked for the independency between rs73862213 and EEFSEC
region (rs10934853), and between rs4826594 and NUT10/11
region (rs5945619); however, both rs73862213 and rs4826594
were statistically independent of the previously reported loci.
Both rs75777376 and rs16901814 in 8q24 region, which exist near
rs12543663, were also independently associated with PCa by
conditional analysis. In addition, the two SNPs newly identified
on chromosome 10 were independent of each other in the
conditional analysis.
In the study, rs114780236 at chr.2 and rs4842687 at
chr.12 showed significant association with Japanese PCa (Sup-
plementary Table 6). But these SNPs were located in regions close
to reported loci, rs58235267 and rs579992126. Since our GWAS
data did not contain the genotypes of rs58235267 and rs5799921,
we could not conduct conditional analysis. Although these loci
were not in complete LD with the reported loci in Japanese (The
R square for rs114780236 and rs58235267 was 0.4701 and the R
square for rs4842687 and rs579921 was 0.6962, respectively), the
relatively high correlation suggests that rs114780236 and
rs4842687 may be in the same susceptibility region with these
reported loci in Japanese.
We examined whether the 167 previously reported PCa related
loci are associated with PCa susceptibility in Japanese using our
GWAS data. We excluded 13 SNPs for which data were not
available and 18 SNPs which showed MAF < 0.01 or were mono-
allelic, leaving 136 SNPs for analysis. We found 68 SNPs showed
weak association (P < 0.05), and 28 SNPs to be strongly associated
with PCa in Japanese after Bonferroni correction (P < 0.00037)
(Supplementary Data 1). We then checked whether the rate of
validation differs by the ethnic group the original report studied
with 85 SNPs. The validation rate was the highest for the SNPs
discovered using Asian cohort (Supplementary Table 7). Of the
75 SNPs found in whites, 34 (46%) were nominally significant at
P < 0.05 in Japanese, with 18 at P < 0.0005. Of the 10 SNPs found



































Fig. 2 Manhattan plot of GWAS. −log10 P value is plotted on the Y-axis.
Each P value is calculated by a 1-degree-freedom Cochran-Armitage test
Genome wide association study
Case: 5088 (BBJ)







Exclude previously reported loci
and same regions
P  < 1×10–5
P  < 5×10–8
Replication study
Case: 4818 (JIKEI, BBJ)
Control: 73,261 (BBJ)
Fig. 1 Scheme for study design and screening results. First, we conducted discovery GWAS followed by imputation using 1000 Genomes Project Phase1 as
a reference. Of the 2997 SNPs that were associated with PCa (P < 1 × 10−5), top 101 SNPs excluding those residing in previously reported loci were
evaluated in the replication study using an independent cohort. A total of 12 SNPs were significantly associated with PCa (P < 5 × 10−8) after meta-analysis
of discovery and replication cohorts
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previously in Asian men, 8 (80%) were nominally significant (P <
0.05) with all at P < 0.0005. The result highlights the large
heterogeneity of PCa associated genetics factors between different
ethnic groups.
Polygenic risk score in Japanese population. Finally, we selected
12 SNPs which were newly discovered in the study and 68 SNPs
which showed nominal association with the Japanese PCa risk
from previously reported SNPs (Supplementary Table 8). Since
our GWAS data did not contain two reported loci, rs58235267
and rs5799921, we also included rs114780236 and rs4842687 to
represent the two regions. We calculated a polygenic risk score
(PRS) by counting the number of risk alleles and their effects in
each individual of the GWAS samples. The distribution of the
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10,682) are shown in Fig. 4a. We defined the upper 5% of the
cases (n= 245) as the genetic high-risk group and the lower 5% as
the low-risk group (n= 245), and examined clinical features of
these genetically risk–stratified groups. Notably, we found that
the mean diagnosis age of the high-risk group was 2.7 years
younger than the non-high risk group (mean age 68.7-year old vs
71.4 year old, P= 6.54 × 10−8, by t-test), while we observed little
difference of mean diagnosis age between the low-risk and non-
low risk groups (72.3 vs 71.1, P= 0.020). We observed the
enrichment of high PRS in early onset PCa cases (P= 0.00221 for
cases with age < 60-year old, by t-test, and P= 4.30 × 10−9 for
cases with age < 65-year old, Fig. 4b). The high-risk group was
also enriched with patients who have a positive family history of
PCa (P= 0.00339, by Fisher test, Fig. 4c). On the other hand,
when we recalculated the PRS using 150 SNPs after adding 68
reported SNPs which indicated no association with Japanese PCa,
statistical association between PRS and early onset PCa in the
high-risk group became weaker (P= 0.02395 for cases with age <
60-year old, by t-test, and P= 3.24 × 10−7 for cases with age < 65-
year old,　Supplementary Fig. 5a). Association between PRS and
positive family history of PCa also declined (P= 0.02395, by
Fisher test, Supplementary Fig. 5b).
Furthermore, we calculated PRS in the PCa cases of the two
validation cohorts (BBJ n= 2386, and JIKEI n= 2218) by
counting the risk allele of 63 SNPs for which genotypes were
available in the replication study (Supplementary Table 8). The
distribution of PRS in both cohorts is shown in Supplementary
Fig. 5c. We confirmed that in both cohorts, the age at diagnosis
for the 5%-high-risk group is approximately 2 years younger than
the non-high risk group (P= 0.023 in BBJ cohort and P= 0.0061
Fig. 3 Locus Explorer plots of novel five GWAS loci. a rs11125927 at chr.2. b rs73862213 at chr.3. c rs4554825 & rs77911174 at chr.10. d rs138708 at chr.22.
The regional association plot (−log10(P) panel) depicts variant P-values relative to chromosomal position. Variants in linkage disequilibrium with the novel
lead SNP(s) at r2≥ 0.1 according to the 1000 Genomes JPT population are shaded in the Manhattan plot and linkage disequilibrium track (LD panel), with
darker color denoting stronger correlation with the lead variant. Lower sections of the plot indicate the relative positions of genes and selected biological
annotations. Annotations displayed are: histone modifications in ENCODE tier 1 cell lines (Histone track), the positions of variants that are eQTLs with
prostate tumor expression in TCGA prostate adenocarcinoma samples (eQTL track), chromatin state categorizations in the PrEC cell-line by ChromHMM
(ChromHMM track), the position of conserved element peaks (Conserved track) and the position of DNaseI hypersensitivity site peaks in ENCODE
prostate cell lines (DNaseI track). Genes on the positive and negative strand are denoted by brown and turquoise color respectively (Gene track). The
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Fig. 4 The distribution of the polygenic risk score (PRS) for PCa in Japanese population. a The PRS distribution of the PCa cases (n= 4893) and the male
control (n= 10,682) of GWAS. Density was estimated using the Gaussian kernel. The 5% higher and lower percentiles are shown as dotted lines. b The
PRS distribution by the age at diagnosis of PCa in the GWAS cases (n= 4762). Density was estimated using the Gaussian kernel. Green, younger than 60
years (n= 129); blue, younger than 65 years (n= 781); gray, 65 years or older (n= 3852). c The PRS distribution by the presence of PCa family history in
the GWAS cases (n= 4893). Density was estimated using the Gaussian kernel. Red, positive PCa family history (n= 272); blue, negative PCa family
history (n= 4621). d The PRS distribution by the age at diagnosis of PCa in the JIKEI validation cohort (n= 2218). Density was estimated using the
Gaussian kernel. Red, younger than 55 years (n= 94); green, younger than 60 years (n= 310); blue, younger than 65 years (n= 802); gray, 65 years or
older (n= 802)
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in JIKEI cohort). We observed that early onset PCa was enriched
in the high PRS group of the BBJ cohort (P= 0.0111 for cases
with age < 60-year old, by t-test, and P= 0.0451 for cases with
age < 65-year old, Supplementary Fig. 5d) and in the JIKEI cohort
(P= 0.00378, for cases with age < 55-year old, P= 0.00119 for
cases with age < 60-year old, and P= 8.90 × 10−5 for cases with
age < 65-year old, by t-test, Fig. 4d).　We also confirmed that the
high-risk group was enriched with patients who have positive
family history of PCa in BBJ replication cohort (P= 0.0281, by
Fisher test, Supplementary Fig. 5e).
Discussions
In this study, we identified 12 new PCa-susceptibility loci in the
Japanese population, but their functional or biological sig-
nificances related to PCa development are still unclear, which is
also the case with many other previously reported loci. Because
most of them are located in non-coding regions and our
expression analysis found only four loci to be weakly related to
expression of nearby genes, these loci are likely associated with
gene regulatory functions.
Among the 12 loci, rs11125927 at chr.2 contained TMEM17
gene in the LD block, which is a cilium associated gene reported
to suppress invasion and migration of non-small cell lung cancer
by restoring Occuludin and Zo-1 expression through inactiva-
tion of ERK-P90RSK-Snail pathway27. rs73862213 at chr.3
contained GATA2 in the same LD block, which plays an
important role in promoting high grade PCa28. In addition to its
role as a transcription factor that promotes androgen receptor
(AR) binding and activation, it regulates a subset of clinically
relevant PCa associated genes in an AR independent manner.
Functionally, GATA2 overexpression promotes cell motility,
migration, growth, tumorigenesis, and therapy resistance in
PCa. rs77911174 at chr.10 region included the ZMIZ1 gene,
which binds to AR and enhances its transcriptional activity in
PCa cells29. In addition, it co-localizes with AR and SUMO1 and
promotes sumoylation of AR in vivo. The same genetic region
has previously been reported to be associated with susceptibility
to colon cancer and breast cancer30,31. Our eQTL analysis
suggested the association of ZMIZ1-AS (antisense) expression
with another independent loci rs4554825, indicating that reg-
ulation of ZMIZ1 expression should be important in prostate
carcinogenesis. The LD block spanning rs11055034 at chr.12
contained the 3’ end of CDKN1B, which is strongly expressed in
non-proliferating cells and plays important roles in the regula-
tion of both quiescence and G1 progression32. It is known to act
as a tumor-suppressor in PCa and suppression of CDKN1B leads
to growth promotion of PCa cells32. rs6117562 at chr.20 was in
the region containing SLC52A3, which is known as a transporter
for riboflavin, however, association with PCa has not been
reported33. rs138708 at chr.22 is a non-synonymous SNP of
SUN2, which is a member of LINK complex and plays an
important role in nuclear-cytoplasmic connection and suppress
Warburg effect in cancer34. Overexpression of SUN2 inhibits
PCa cell growth and SUN2 knockdown promotes PCa growth35.
The LD block spanning rs4826594 at chr.X included three genes,
FGD1, GNL3L, and TSR2. Fgd1 is transiently associated with
invadopodia and required for their formation and function in
extracellular matrix degradation and acts by direct modulation
of Cdc42 activation36. FGD1 is overexpressed in human prostate
and breast cancer and is associated with tumor aggressiveness36.
GNL3L has been reported to directly bind to and stabilize
MDM2 protein, however its role in PCa has not been studied37.
TSR2 is known to enhance apoptosis by suppressing NF-kB
signaling in laryngeal cancer38. The genes listed above
potentially influence PCa development and further functional
analysis is warranted.
Polygenic risk estimation by using common variants for PCa
has been attempted. For breast cancer, PRS consisting of 77 SNPs
tested in 33,000 cases demonstrated significant interaction
between PRS and age and family history39. Genetic risk predic-
tion of PCa was first reported using five common susceptibility
variants40, which was established by simply counting the number
of risk alleles. Subsequently, models incorporated increasing
number of the significant variants15, and some models uses much
more variants including the variants that are not significant at the
genome-wide level41. It is still controversial which and how many
variants should be used for PRS42. Ethnic-specific or genomic
structure-specific information is also an important issue for PRS.
In this study for PRS we used 82 SNPs which were statistically
associated with PCa in Japanese population and found that early
onset and familial PCa were enriched in the high-risk group in
Japanese population. Early onset and familial PCa, with which
genetic factors should be more involved, was reported to be
enriched in cases with rare variants of BRCA2 and HOXB13 in
Caucasian population4,5. However, this is the first report to show
that risk assessment using 50~ common variants may explain
hereditary phenotype of PCa.　In addition, PRS using 82 SNPs
which are associated with Japanese PCa showed stronger asso-
ciation with early onset PCa and positive family history of PCa
than PRS with 150 SNPs which also included the SNPs that failed
to show association with Japanese PCa. The result suggests that
more precise selection of patients with high risk of developing
PCa may be possible with ethnic population-specific PRS. Early
onset PCa is often more aggressive and may have a different
etiology than later-onset PCa43. Among men diagnosed with high
grade and advanced stage PCa, men with early onset PCa are
more likely to die of their cancer, with higher cause-specific
mortality than later-onset disease43. In addition, familial PCa
accounts for a greater proportion of PCa in early onset cases than
it does in men diagnosed at older ages. These PCas have been
shown to have a more significant genetic component indicating
that this group may benefit the most from evaluation of
genetic risk44. Since the PRS model is useful for the early detec-
tion of early onset PCa and familial PCa, PRS might have a
greater impact on the clinical examination and treatment of PCa.
However, further replication of this risk-stratification by other
larger cohort is required before the model is applied to
clinical use.
As with other GWAS for PCa, contamination of control with
undiagnosed PCa is a limitation of our study. In Japan, as with
western countries, increasing number of PCa are detected by PSA
screening. However, it is estimated that still less than 50% of
males over 50 are actually exposed to PSA screening in Japan, and
10% of newly diagnosed PCa patients present with metastatic
disease. Therefore, it is likely that the control in this study
includes undiagnosed PCa cases to certain extent. This certainly
implies that the SNPs identified in this study is potentially
associated with factors other than PCa carcinogenesis, such as
health consciousness to receive screening. Continuing efforts
should be made to reveal the biological significance of each SNPs
reported in GWAS studies including this study, which hopefully
delineate the complex interaction between genetic susceptibility
and environmental exposure.
In summary, we have conducted a large-scale GWAS for
Japanese and identified 12 PCa susceptibility loci that have not
been reported previously. We stratified the polygenic risk for
Japanese PCa patients by using 82 associated-SNPs and indicated
that early onset and familial PCa cases were enriched in the
genetically high-risk population.
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Methods
Study population. GWAS included 5088 cases from BioBank Japan, which was
established in the Institute of Medical Science at the University of Tokyo16,17.
Among the 5088 cases for the GWAS, 272 (5.3%) subjects had a family history of
PCa, 1219 (23.9%) subjects revealed PSA ≥ 10 and 1989 (39.1%) subjects were
diagnosed to have cancer with Gleason score of 7 or higher (Supplementary
Table 1). From the BBJ, pathologically proven PCa cases were selected. Non-cancer
controls were from three population-based cohorts, including the J-MICC study18,
the JPHCStudy19, IMM, and ToMMo20. Genomic DNA samples were extracted
from peripheral blood leukocytes and normal tissues using a standard method. All
participating studies obtained informed consent from all participants by following
the protocols approved by their institutional ethical committees before enrollment,
and the ethical committees at each institute approved the project (BBJ: https://
biobankjp.org/english/index.html, J-MICC: http://www.jmicc.com/en/, JPHC:
https://epi.ncc.go.jp/en/jphc/index.html, IMM: http://iwate-megabank.org/
en/, ToMMo: https://www.megabank.tohoku.ac.jp/english/).
Genotyping and quality control. GWAS was conducted using Illumina
OmniExpress Exome or the OmniExpress+HumanExome BeadChip (Illumina
Inc., San Diego, California, U.S.). Of the 947,830 SNPs genotyped, 195,588 were
mono-allelic and were excluded from further analysis. Cluster plots of the top 100
SNPs showing the smallest P-values were checked by visual observation, and
604,992 SNPs met the criteria of call rate≧ 0.99 both in case and control samples.
Finally, SNPs P≧ 1.00 × 10−6 in a Hardy-Weinberg Equilibrium test were selected.
Association study was performed for the total of 523,051 SNPs.
Imputation of the un-genotyped SNPs was conducted by MaCH45 and
minimac46 using the data from the JPT/CHS/CHD subjects and using the 1000
Genome Project Phase 1 (release 16 March 2012) as a reference. We exclude SNP
with a large allele frequency difference between the reference panel and the GWAS
(>0.16)47. We also excluded SNPs with low imputation quality score (R square <
0.3) and insertion/deletion polymorphisms.
Samples and genotyping for the replication studies. We conducted a replication
study using independent 4818 PCa cases and 73,261 controls. Case samples were
obtained from the BioBank Japan (2236 cases) and JIKEI samples (2582 samples)
from The Jikei University School of Medicine. The JIKEI sample has been
described previously with new samples being added for this study48. All cases were
histologically diagnosed by local pathologists, and clinical data were collected by
local urologists. Controls in the replication study were the 73,261 male samples
from BBJ that were subjected to GWAS for diseases other than PCa.
A multi-index PCR-based target sequencing method was used to sequence the
target region of case samples49. We used a two-step PCR method to construct
DNA libraries. The 1st PCR (25 cycle) was performed with 202 primer pairs and
2X Platinum Multiplex PCR Master Mix (Thermo Fisher Scientific) to amplify
the target region, followed by the 2nd PCR (4 cycle) with 8-bp barcode and
adapter sequences added using primers targeting shared 5’ overhangs introduced
during the 1st PCR and KAPA HiFi HotStart DNA Polymerase (KAPA). After
purification and quantification of pooled libraries, we sequenced them by 2 150-
bp paired-end reads on a HiSeq 2500 (Illumina) instrument. Sequence reads
allocated to each individual were aligned to the human reference sequence (hg19)
using Burrows-Wheeler Aligner (ver. 0.7.12) and processed using Genome
Analysis Toolkit (GATK, ver. 3.4–46)50,51. For quality control, we selected
individuals in which more than 98% of the target region was covered with 20 or
more sequencing reads. We called variants of each individual separately using
UnifiedGenotyper and HaplotypeCaller of GATK, and VCMM (ver. 1.0.2)52.
Genotypes for all individuals were jointly determined for each variant based on
the sequencing read ratio of reference and alternative alleles. When the
alternative allele frequency was between 0 and 0.15, between 0.25 and 0.75, and
between 0.85 and 1, we assigned homozygote of the reference allele, heterozygote,
and homozygote of the alternative allele, respectively. The SNPs that could not be
analyzed by multi-index sequencing were genotyped by multiplex PCR-based
invader assay53. The five SNPs that could not be genotyped by both assays were
excluded in the replication study.
Statistical analysis. In all stages, association of each SNP was assessed under an
additive model.　In the GWAS, the genetic inflation factor λGC was derived from
P-values obtained by the Cochran-Armitage trend test for all the tested SNPs. The
quantile–quantile plot was drawn using the R program. λGC 1000 was calculated
using the following formula:54
λGC 1000 ¼ 1þ 1 λGC obsð Þ ´ ð1=ncases þ 1=ncontrolsÞ=ð1=1000caes þ 1=1000controlsÞ:
Odds ratios were calculated using the non-effect alleles as references, unless stated
otherwise. The results of the combined analyses of the GWAS and the replication
study were verified by the Mantel–Haenszel method. Heterogeneity across the two
stages was examined using P-link55. We considered P= 5 × 10−8 (GWAS and
meta-analysis) as the significance threshold after Bonferroni correction for multiple
testing.
Polygenic risk score. Polygenic score was computed as the weighted sum of the
number of risk alleles. Log odds ratios computed in the GWAS part of this study
were used as the weights. The number of incorporated SNPs was 82 and 63 in the
GWAS and the validation cohorts, respectively (Supplementary Table 8). For
imputed alleles in GWAS, dosage values were used as the number of risk alleles.
Statistical association between polygenic score and clinical information was ana-
lyzed using the statistical software R56.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
GWAS summary statistics of prostate cancer will be publicly available at our website
(JENGER, http://jenger.riken.jp/en/) and the National Bioscience Database Center
(NBDC, https://humandbs.biosciencedbc.jp/en/) Human Database. Genotype data of
case samples are available at NBDC under research ID hum0014.
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